Medidata Solutions Rave 5.4: Fitting EDC to a T IDC Life Science Insights
A new wave of companies is poised to move to EDC
A majority of pharma and biotech companies will be making the move to Electronic Data Capture (EDC) technology within the next 12 months. Although these industries have historically regarded EDC as too risky, the FDA's Critical Path initiative and the emergence of data interoperability standards have demonstrated the EDC value proposition. Companies increasingly recognize the difficulty and cost of maintaining homegrown, highly customized systems, and are attracted to the availability of mature, vendor-supplied systems that meet the functionality and organization process support needs of clinical trial sponsors. Innovative vendors like Medidata Solutions are well positioned to serve the cautious majority of pharma and biotech companies with the ultra-thin client designs, service-oriented architecture and integrated data standards as in Medidata Rave 5.4.
